ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Li, Jia-Xin; Li, Run-Ze; Ma, Lin-Rui; Wang, Peng; Xu, Dong-Han; Huang, Jie; Li, Li-Qi; Tang, Ling; Xie, Ying; Leung, Elaine Lai-Han*; Yan, Pei-Yu*广东省人民医院; 广州中医药大学; 南方医科大学
Frontiers in Pharmacology2022-4-20DOI: 10.3389/fphar.2022.875330
2被引6阅读
引用收藏
分享

摘要

In the past few decades, several gene mutations, including the anaplastic lymphoma kinase, epidermal growth factor receptor, ROS proto-oncogene 1 and rat sarcoma viral oncogene homolog (RAS), have been discovered in non-small cell lung cancer (NSCLC). Kirsten rat sarcoma viral oncogene homolog (KRAS) is the isoform most frequently altered in RAS-mutated NSCLC cases. Due to the structural and biochemical characteristics of the KRAS protein, effective approaches to treating KRAS-mutant NSCLC still remain elusive. Extensive recent research on KRAS-mutant inhibitors has made a breakthrough in identifying the covalent KRAS(G1)(2C) inhibitor as an effective agent for the treatment of NSCLC. This review mainly concentrated on introducing new covalent KRAS(G1)(2C) inhibitors like sotorasib (AMG 510) and adagrasib (MRTX 849); summarizing inhibitors targeting the KRAS-related upstream and downstream effectors in RAF/MEK/ERK pathway and PI3K/AKT/mTOR pathway; exploring the efficacy of immunotherapy and certain emerging immune-related therapeutics such as adoptive cell therapy and cancer vaccines. These inhibitors are being investigated in clinical trials and have exhibited promising effects. On the other hand, naturally extracted compounds, which have exhibited safe and effective properties in treating KRAS-mutant NSCLC through suppressing the MAPK and PI3K/AKT/mTOR signaling pathways, as well as through decreasing PD-L1 expression in preclinical studies, could be expected to enter into clinical studies. Finally, in order to confront the matter of drug resistance, the ongoing clinical trials in combination treatment strategies were summarized herein.

学科与关键词

关键词
non-small cell lung cancerKRAScovalent KRAS(G12C) inhibitorimmunotherapynatural compoundcombination treatment
相关
加载中…
  • Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
    Zheng, Xinting; Luo, Jiamin; Liu, Wei; Ashby, Charles R., Jr.; Chen, Zhe-Sheng*; Lin, Lizhu*DRUGS OF TODAY, 2022, 58(4): 175-185.被引 10
  • High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer
    Feng, H.; Chen, Y.; Xie, Z.; Jiang, J.; Zhong, Y.; Gao, L.; Zhou, W.; Guo, W.; Yan, W.; Lv, Z.; Lu, D.; Liang, H.; Xu, F.; Yang, J.; Yang, X.; Zhou, Q.; Zhang, D.; Zhang, Z.; Chuai, S.; Zhang, H.; Wu, Y.; Zhang, X.
  • Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
    Zhou, Q.; Meng, X.; Sun, L.; Huang, D.; Yang, N.; Yu, Y.; Zhao, M.; Zhuang, W.; Hu, Y.; Pan, Y.; Sun, M.; Shan, J.; Guo, R-H.; Chu, Q.; Xu, C.; Lin, J.; Huang, J.; Huang, M.; Shen, Y.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-04-20
卷期
第 13 卷
页码
875330
DOI
10.3389/fphar.2022.875330
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Science and Technology Development Fund, Macau SAR SAR (SKL-QRCM (MUST)-2020-2022); Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery [0011/2021/A, 0096/2018/A3, 001/2020/ALC]; 2020 Young Qihuang Scholar award - National Administration of Traditional Chinese Medicine of PRC

作者

  • L

    Li, Jia-Xin (第一作者)

  • L

    Li, Run-Ze

    2 · guangdong prov acad chinese med sci · guangdong prov hosp · guangzhou univ chinese med

查看全部 11 位作者收起作者
  • M

    Ma, Lin-Rui

  • W

    Wang, Peng

  • X

    Xu, Dong-Han

  • H

    Huang, Jie

  • L

    Li, Li-Qi

  • T

    Tang, Ling

    southern med univ

  • X

    Xie, Ying

    2 · guangdong prov acad chinese med sci · guangdong prov hosp · guangzhou univ chinese med

  • L

    Leung, Elaine Lai-Han (通讯)

  • Y

    Yan, Pei-Yu (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417